MedPath

To study the medicinal effectiveness of SafÅ«f Hajar-al YahÅ«d in patients of HasÄ?h al-Kulya (Nephrolithiasis).

Phase 2
Conditions
Health Condition 1: N200- Calculus of kidneyHealth Condition 2: null- HasÄ?h al-Kulya (Nephrolithiasis)
Registration Number
CTRI/2015/10/006276
Lead Sponsor
Central Council for Research in Unani Medicine CCRUM New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Patients with HasÄ?h al-Kulya (nephrolithiasis) as diagnosed by X-Ray/Ultrasound KUB with calculi measuring between 3 to 6 mm with or without any of the following symptoms:

•Bawl al-Dam (Haematuria)

•Siqlâ?? al-Khasira (Heaviness in the Loin)

•Wajaâ?? al-Khasira (Pain in the Loin)

•History of Recurrent UTI

•History of Recurrence of Renal Stone

•Urine showing Calcium Crystaluria

Exclusion Criteria

•Patients having acute condition of nephrolithiasis

•Complicated cases of nephrolithiasis requiring surgical intervention

•Patients with hydronephrosis, acute symptoms of UTI or any other renal diseases

•Patients with serum creatinine > 2mg%

•Patients on long-term medications

•Patients with cardiac, pulmonary or hepatic diseases

•Pregnancy and lactation

•Alcohol or drug abuse/ History of alcohol or drug abuse within 6 months prior to baseline

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Anti-nephrolithic potential of Safūf Hajar-al Yahūd by using osteopontin, oxidative stress markers (Glutathione, Malondialdehyde, Superoxide dismutase) and electrolytes (Sodium, Potassium, Calcium, Phosphorous, Magnesium, Chloride).Timepoint: 8 WEEKS
Secondary Outcome Measures
NameTimeMethod
This study will help us to observe the role of osteopontin, oxidative stress markers and electrolytes in HasÄ?h al-Kulya (Nephrolithiasis).Timepoint: 8 WEEKS
© Copyright 2025. All Rights Reserved by MedPath